Saturday 17 October 2026
Export REVB’s income statement to Excel — free account
Revelation Biosciences, Inc.
REVB Healthcare Biotechnology
In the quarter to June 2026, EPS grew 96.9% and free cash flow fell 35.3%, each against the same quarter a year earlier.
0.49
0.27
−35.53%
Follow REVB
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (276.43%) | (271.02%) | (219.10%) | (205.92%) |
+8 more TTM periods Free account |
|
| (214.63%) | (226.19%) | (163.31%) | (143.70%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(192.48%) | (166.32%) | (168.32%) | (127.98%) | |
Free Cash Flow per Share |
(2.47) | (2.73) | (13.32) | (15.20) | |
Free Cash Flow |
(9.44) | (8.76) | (8.27) | (10.05) | |
Capital Expenditures |
(0.11) | (0.07) | — | — | |
| Other line items | |||||
Cash ROIC |
(43.80%) | (32.33%) | (42.28%) | (42.39%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.49 | 0.40 | 0.56 | 0.71 | |
Depreciation/Fixed assets |
0.16 | 0.19 | 1.50 | 1.19 | |
Capex/Depreciation |
(3.95) | (2.65) | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.44) | (2.71) | (13.32) | (15.20) | |
Capex per Share |
(0.03) | (0.02) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates